Purinergic signaling in cognitive impairment and neuropsychiatric symptoms of Alzheimer's disease

Autor(es):Mostrar menos -

Ribeiro, Deidiane Elisa ; Petiz, Lyvia Lintzmaier ; Glaser, Talita ; Oliveira-Giacomelli, Agatha ; Andrejew, Roberta ; Saab, Fernando de Azevedo Ribeiro ; Milanis, Milena da Silva ; Campos, Henrique Correia ; Sampaio, Vanessa Fernandes Arnaud ; La Banca, Sophia ; Longo, Beatriz Monteiro ; Lameu, Claudiana ; Tang, Yong ; Resende, Rodrigo Ribeiro ; Ferreira, Sergio T. ; Ulrich, Henning

• Tipo de documento: Artigo Científico
• Fonte: Neuropharmacology; v. 226, p. 16-pg., 2023-01-12.

Resumo

About 10 million new cases of dementia develop worldwide each year, of which up to 70% are attributable to Alzheimer's disease (AD). In addition to the widely known symptoms of memory loss and cognitive impairment, AD patients frequently develop non-cognitive symptoms, referred to as behavioral and psychological symptoms of dementia (BPSDs). Sleep disorders are often associated with AD, but mood alterations, notably depression and apathy, comprise the most frequent class of BPSDs. BPSDs negatively affect the lives of AD patients and their caregivers, and have a significant impact on public health systems and the economy. Because treatments currently available for AD are not disease-modifying and mainly aim to ameliorate some of the cognitive symptoms, elucidating the mechanisms underlying mood alterations and other BPSDs in AD may reveal novel avenues for progress in AD therapy. Purinergic signaling is implicated in the pathophysiology of several central nervous system (CNS) disorders, such as AD, depression and sleep disorders. Here, we review recent findings indicating that purinergic receptors, mainly the A1, A2A, and P2X7 subtypes, are associated with the development/progression of AD. Current evidence suggests that targeting purinergic signaling may represent a promising therapeutic approach in AD and related conditions. (AU)

• Processo FAPESP: 18/07366-4 - Receptores de purinas e cininas como alvos de estudo e intervenção terapêutica em doenças neurológicas
• Beneficiário: Alexander Henning Ulrich
• Modalidade de apoio: Auxílio à Pesquisa - Temático
• Processo FAPESP: 18/08426-0 - Alcalóides indólicos, subprodutos do processamento de Maqui (Aristotelia chilensis) como aditivos alimentares no tratamento da Doença de Alzheimer
• Beneficiário: Alexander Henning Ulrich
• Modalidade de apoio: Auxílio à Pesquisa - Regular
• Processo FAPESP: 18/17504-5 - Efeitos comportamentais e moleculares da modulação farmacológica dos receptores P2Y2 em modelo animal da Doença de Alzheimer
• Beneficiário: Deidiane Elisa Ribeiro
• Modalidade de apoio: Bolsas no Brasil - Pós-Doutorado
• Processo FAPESP: 15/19128-2 - Mecanismos de metástase de tumores infantis para a medula óssea
• Beneficiário: Claudiana Lameu
• Modalidade de apoio: Auxílio à Pesquisa - Jovens Pesquisadores